Published in Cancer Res on July 15, 2012
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res (2015) 1.52
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One (2013) 1.50
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res (2013) 1.29
Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun (2014) 1.05
RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer. Oncotarget (2014) 1.04
RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol (2015) 1.03
Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res (2013) 1.01
Comprehensive characterization of the Published Kinase Inhibitor Set. Nat Biotechnol (2015) 1.00
Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS One (2014) 0.97
Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. Proc Natl Acad Sci U S A (2014) 0.95
NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PLoS One (2014) 0.93
Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst) (2015) 0.93
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res (2015) 0.92
Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther (2014) 0.92
Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell (2013) 0.90
Stereochemical Studies of the Karlotoxin Class Using NMR Spectroscopy and DP4 Chemical-Shift Analysis: Insights into their Mechanism of Action. Angew Chem Int Ed Engl (2015) 0.90
Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis (2015) 0.89
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis Markers (2014) 0.89
Estimating the activity of transcription factors by the effect on their target genes. Bioinformatics (2014) 0.89
miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene (2015) 0.88
An appraisal of RECQ1 expression in cancer progression. Front Genet (2014) 0.88
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS One (2014) 0.87
Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics (2013) 0.87
Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. Bioinformatics (2015) 0.87
Cancer stem cell division: when the rules of asymmetry are broken. Stem Cells Dev (2014) 0.86
Highly Selective Synthesis of Halomon, Plocamenone, and Isoplocamenone. J Am Chem Soc (2015) 0.86
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget (2015) 0.86
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res (2015) 0.84
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1). J Med Chem (2012) 0.84
Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst) (2013) 0.84
Human germline and pan-cancer variomes and their distinct functional profiles. Nucleic Acids Res (2014) 0.84
(-)-Englerin A-evoked Cytotoxicity is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase. J Biol Chem (2016) 0.84
Meta-analysis using a novel database, miRStress, reveals miRNAs that are frequently associated with the radiation and hypoxia stress-responses. PLoS One (2013) 0.81
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med (2016) 0.81
Public data and open source tools for multi-assay genomic investigation of disease. Brief Bioinform (2015) 0.80
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer (2014) 0.80
rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. Bioinformatics (2015) 0.80
Feature selection and classifier performance on diverse bio- logical datasets. BMC Bioinformatics (2014) 0.79
The emerging role of QSOX1 in cancer. Antioxid Redox Signal (2014) 0.79
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib. PLoS One (2015) 0.78
Designing of promiscuous inhibitors against pancreatic cancer cell lines. Sci Rep (2014) 0.78
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis. Neoplasia (2014) 0.78
Functional Identification of Target by Expression Proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci Rep (2015) 0.78
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem (2014) 0.78
Drug target inference through pathway analysis of genomics data. Adv Drug Deliv Rev (2013) 0.78
Nanoparticle analysis sheds budding insights into genetic drivers of extracellular vesicle biogenesis. J Extracell Vesicles (2016) 0.77
Prediction errors in learning drug response from gene expression data - influence of labeling, sample size, and machine learning algorithm. PLoS One (2013) 0.77
Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. Oncotarget (2016) 0.77
Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins. Asian J Androl (2016) 0.77
A survey on the computational approaches to identify drug targets in the postgenomic era. Biomed Res Int (2015) 0.77
Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. Nucleic Acids Res (2015) 0.77
MPINet: metabolite pathway identification via coupling of global metabolite network structure and metabolomic profile. Biomed Res Int (2014) 0.77
Usp7 protects genomic stability by regulating Bub3. Oncotarget (2014) 0.77
Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes. Medicine (Baltimore) (2016) 0.77
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget (2015) 0.77
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci Rep (2016) 0.77
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med (2017) 0.76
In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes. Oncoscience (2016) 0.76
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Front Pharmacol (2016) 0.76
SOX5 is involved in balanced MITF regulation in human melanoma cells. BMC Med Genomics (2016) 0.76
The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways. PLoS One (2015) 0.76
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. PLoS One (2017) 0.75
Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Oncotarget (2016) 0.75
Prediction of Candidate Drugs for Treating Pancreatic Cancer by Using a Combined Approach. PLoS One (2016) 0.75
Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Inform (2016) 0.75
The use of novel selectivity metrics in kinase research. BMC Bioinformatics (2017) 0.75
Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun (2017) 0.75
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells. Sci Rep (2015) 0.75
Molecular Classification of Lobular Carcinoma of the Breast. Sci Rep (2017) 0.75
Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line. Nucleic Acids Res (2016) 0.75
Development of a prediction model for radiosensitivity using the expression values of genes and long non-coding RNAs. Oncotarget (2016) 0.75
K-Ras Activation Induces Differential Sensitivity to Sulfur Amino Acid Limitation and Deprivation and to Oxidative and Anti-Oxidative Stress in Mouse Fibroblasts. PLoS One (2016) 0.75
Bioinformatics of Cancer ncRNA in High Throughput Sequencing: Present State and Challenges. Front Genet (2012) 0.75
A Database of Gene Expression Profiles of Korean Cancer Genome. Genomics Inform (2015) 0.75
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
Nonlinear quantitative radiation sensitivity prediction model based on NCI-60 cancer cell lines. ScientificWorldJournal (2014) 0.75
Early spatiotemporal-specific changes in intermediate signals are predictive of cytotoxic sensitivity to TNFα and co-treatments. Sci Rep (2017) 0.75
Chromatin Regulators as a Guide for Cancer Treatment Choice. Mol Cancer Ther (2016) 0.75
Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World J Clin Oncol (2015) 0.75
Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. ACS Chem Biol (2016) 0.75
Handling missing rows in multi-omics data integration: multiple imputation in multiple factor analysis framework. BMC Bioinformatics (2016) 0.75
Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy. PLoS One (2016) 0.75
Ophiobolin A, a sesterpenoid fungal phytotoxin, displays different mechanisms of cell death in mammalian cells depending upon the cancer cell origin. Int J Oncol (2017) 0.75
A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Rep (2016) 0.75
Transcriptional profiling reveals elevated Sox2 in DNA polymerase ß null mouse embryonic fibroblasts. Am J Cancer Res (2012) 0.75
Interrogating the topological robustness of gene regulatory circuits by randomization. PLoS Comput Biol (2017) 0.75
The NCI-60 Methylome and its Integration into CellMiner. Cancer Res (2016) 0.75
Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia (2015) 0.75
CancerResource-updated database of cancer-relevant proteins, mutations and interacting drugs. Nucleic Acids Res (2015) 0.75
Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. Pharmacol Rev (2017) 0.75
Mathematical deconvolution uncovers the genetic regulatory signal of cancer cellular heterogeneity on resistance to paclitaxel. Mol Genet Genomics (2017) 0.75
Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res (2017) 0.75
Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids. Invest New Drugs (2014) 0.75
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell (2001) 10.02
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol (2005) 5.63
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
The microcosmos of cancer. Nature (2012) 4.50
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38
ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene (2010) 2.25
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer (2010) 1.78
Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem (2006) 1.70
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol (2011) 1.57
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer (2011) 1.44
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer. Int J Oncol (2004) 1.31
MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res (2010) 1.26
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res (2010) 1.24
Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev (2010) 1.22
Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci (2011) 1.18
Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes. PLoS One (2012) 1.13
Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol (2010) 1.07
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther (2005) 1.04
CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene (2011) 1.03
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Res (2011) 1.00
Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther (2010) 0.97
Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines. PLoS One (2012) 0.94
Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One (2011) 0.93
Induced resistance in leukaemia L1210 to adriamycin and its cross-resistance to vincristine and bouvardin. Chemotherapy (1982) 0.88
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. Anticancer Res (2012) 0.86
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Invest New Drugs (2003) 0.80
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
Overview of BioCreative II gene mention recognition. Genome Biol (2008) 5.67
Framework for a protein ontology. BMC Bioinformatics (2007) 5.24
Overview of BioCreative II gene normalization. Genome Biol (2008) 5.05
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
The gene normalization task in BioCreative III. BMC Bioinformatics (2011) 2.89
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Gene name ambiguity of eukaryotic nomenclatures. Bioinformatics (2004) 2.72
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res (2003) 2.50
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene (2004) 2.36
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 2.07
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
iProLINK: an integrated protein resource for literature mining. Comput Biol Chem (2004) 1.96
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Machine learning and word sense disambiguation in the biomedical domain: design and evaluation issues. BMC Bioinformatics (2006) 1.93
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
BioTagger-GM: a gene/protein name recognition system. J Am Med Inform Assoc (2008) 1.81
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Using machine learning for concept extraction on clinical documents from multiple data sources. J Am Med Inform Assoc (2011) 1.76
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis. J Am Med Inform Assoc (2012) 1.73
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) (2003) 1.70
Calculating confidence intervals for prediction error in microarray classification using resampling. Stat Appl Genet Mol Biol (2008) 1.70
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet (2010) 1.66
Normalization and standardization of electronic health records for high-throughput phenotyping: the SHARPn consortium. J Am Med Inform Assoc (2013) 1.64
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res (2003) 1.54
HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem (2009) 1.53
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res (2010) 1.53
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res (2007) 1.53
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Bloom's syndrome helicase and Mus81 are required to induce transient double-strand DNA breaks in response to DNA replication stress. J Mol Biol (2007) 1.50
VennMaster: area-proportional Euler diagrams for functional GO analysis of microarrays. BMC Bioinformatics (2008) 1.49
Endogenous gamma-H2AX-ATM-Chk2 checkpoint activation in Bloom's syndrome helicase deficient cells is related to DNA replication arrested forks. Mol Cancer Res (2007) 1.46
Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol (2004) 1.46
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) (2006) 1.45
Genome-wide depletion of replication initiation events in highly transcribed regions. Genome Res (2011) 1.44
Coreference analysis in clinical notes: a multi-pass sieve with alternate anaphora resolution modules. J Am Med Inform Assoc (2012) 1.44
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem (2008) 1.43
Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage. Mol Cell Biol (2005) 1.40
Identification of novel mutations by exome sequencing in African American colorectal cancer patients. Cancer (2014) 1.39
Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol (2008) 1.39
Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem (2005) 1.38
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry (2010) 1.38
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS (2011) 1.38
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (2011) 1.37
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res (2002) 1.37
dbOGAP - an integrated bioinformatics resource for protein O-GlcNAcylation. BMC Bioinformatics (2011) 1.36
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol (2011) 1.36
Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem (2006) 1.36
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. EMBO J (2010) 1.36